Kali-Extracts Hemp4mula CBD Infused Gum For Sale On USMJ.com Next Week
April 11 2019 - 9:00AM
InvestorsHub NewsWire
Kali-Extracts Hemp4mula CBD Infused
Gum For Sale On USMJ.com Next Week
Dallas, TX
-- April 11, 2019 -- InvestorsHub NewsWire -- Kali-Extracts, Inc.
(Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC:
KALY) (“KALY”) is a health and
wellness company set to generate revenue from its patented cannabis
extraction technology through overlapping go-to-market
strategies. In addition to developing pharmaceutical
products, KALY is utilizing is patented cannabis extraction process
to develop numerous wellness products. Earlier this year KALY
announced a $100,000 wholesale order of its Hemp4mula CBD infused
gum and plans to retail the gum on USMJ.com, the cannabis sector Ecommerce
site from North American Cannabis Holdings, Inc. (USOTC:
USMJ) (aka USMJ). Today KALY is pleased to announce it
has caught up on its Hemp4mula gum production and has product in
inventory now that will be listed for sale from USMJ.com next week. After making a
series of announcements about its cannabis extract research and
development, KALY reemphasized today its multiple go-to-market
strategy to generate near term revenues from its health and
wellness products in addition to developing long-term revenues from
its pharmaceutical developments.
KALY has
recently announced ongoing cannabis extract research and
development targeting four specific health issues: Chronic
Obstructive Pulmonary Disease (COPD); Type 2 Diabetes; Cancer Pain
Management, and Epilepsy. The market for Type 2 Diabetes is
expected to be a $64 billion market by 2026. The market
for COPD treatment is anticipated to reach $14 billion by 2025. The overall pain management treatment market is
anticipated to reach $83 billion by 2024. The market for
epilepsy treatment is anticipated to reach $9 billion by 2022. The company has
scheduled an online prestation next week for Wednesday, April
17th, where management will provide details on its
patented cannabis extract treatments targeting a $170 million
pharmaceutical market opportunity currently under development.
The company has scheduled an online prestation next week for
Wednesday, April 17th, where management will provide
details on its patented cannabis extract treatments targeting a
$170 million pharmaceutical market opportunity currently under
development.
Beyond the
four specific cannabis therapies currently in various stages of
research and development, KALY has a number of additional target
therapies in its research pipeline which will be highlighted in the
April 17tt presentation.
To learn more about the company
visit https://www.kali-extracts.com/
This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended (the "Exchange Act"),
and as such, may involve risks and uncertainties. These forward
looking statements relate to, amongst other things, current
expectation of the business environment in which the company
operates, potential future performance, projections of future
performance and the perceived opportunities in the market. The
company's actual performance, results and achievements may differ
materially from the expressed or implied in such forward-looking
statements as a result of a wide range of
factors.
CONTACT:
Frederick Ferri
ir@kali-extracts.com
(214) 210-0459
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Apr 2023 to Apr 2024